| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |